ERBB2 and gastric cancer: For example, 1 trastuzumab is the first drug to be applied in targeted therapy of gastric cancer, which targets HER2 (111); 2 ramucirumab was approved by the U.S. FDA in 2014 for the treatment of advanced gastric cancer, which is an anti-VEGF-R2 monoclonal antibody that inhibits the binding of this receptor to VEGF to inhibit its activation and enable the angiogenesis effect of VEGF could not be achieved, resulting in multiple effects of anti-tumor blood vessels (112).